Axerion Therapeutics, Inc. is a biotechnology company focused on developing innovative therapeutics for neurological diseases and injuries with significant unmet medical need, including Alzheimer’s disease and spinal cord injury.

Axerion’s Prion Protein (PrP) project is a novel potential therapeutic approach for patients suffering from Alzheimer’s disease. Axerion is developing small molecule oral compounds to block the binding of ß-amyloid (Aß) oligomers (clumps of Aß peptides) to PrP in the brain, thereby preventing a cascade of events that result in brain dysfunction. Axerion’s technology, if successful, could help slow or halt cognitive decline in Alzheimer’s patients.

With its Nogo Receptor platform, Axerion is developing treatments that have the potential to stimulate regrowth in axons, which are long cellular fibers that electrically connect one nerve cell to another and play a vital role in supporting neurological function. These potential treatments could help to restore function in patients who are suffering from spinal cord injuries, stroke and other central nervous system disorders.

Axerion was established in New Haven to develop and commercialize intellectual property licensed from Dr. Stephen Strittmatter’s laboratory at Yale University.

Website: http://www.axeriontherapeutics.com